IBDEI10Q ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16943,0)
 ;;=M79.1^^88^856^93
 ;;^UTILITY(U,$J,358.3,16943,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16943,1,3,0)
 ;;=3^Myalgia
 ;;^UTILITY(U,$J,358.3,16943,1,4,0)
 ;;=4^M79.1
 ;;^UTILITY(U,$J,358.3,16943,2)
 ;;=^5013321
 ;;^UTILITY(U,$J,358.3,16944,0)
 ;;=G72.1^^88^856^94
 ;;^UTILITY(U,$J,358.3,16944,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16944,1,3,0)
 ;;=3^Myopathy,Alcoholic
 ;;^UTILITY(U,$J,358.3,16944,1,4,0)
 ;;=4^G72.1
 ;;^UTILITY(U,$J,358.3,16944,2)
 ;;=^5004096
 ;;^UTILITY(U,$J,358.3,16945,0)
 ;;=G72.81^^88^856^95
 ;;^UTILITY(U,$J,358.3,16945,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16945,1,3,0)
 ;;=3^Myopathy,Critical Illness
 ;;^UTILITY(U,$J,358.3,16945,1,4,0)
 ;;=4^G72.81
 ;;^UTILITY(U,$J,358.3,16945,2)
 ;;=^328484
 ;;^UTILITY(U,$J,358.3,16946,0)
 ;;=G72.0^^88^856^96
 ;;^UTILITY(U,$J,358.3,16946,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16946,1,3,0)
 ;;=3^Myopathy,Drug-Induced
 ;;^UTILITY(U,$J,358.3,16946,1,4,0)
 ;;=4^G72.0
 ;;^UTILITY(U,$J,358.3,16946,2)
 ;;=^5004095
 ;;^UTILITY(U,$J,358.3,16947,0)
 ;;=G72.41^^88^856^97
 ;;^UTILITY(U,$J,358.3,16947,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16947,1,3,0)
 ;;=3^Myopathy,Inclusion Body Myositis
 ;;^UTILITY(U,$J,358.3,16947,1,4,0)
 ;;=4^G72.41
 ;;^UTILITY(U,$J,358.3,16947,2)
 ;;=^5004098
 ;;^UTILITY(U,$J,358.3,16948,0)
 ;;=G72.49^^88^856^98
 ;;^UTILITY(U,$J,358.3,16948,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16948,1,3,0)
 ;;=3^Myopathy,Inflammatory/Immune NEC
 ;;^UTILITY(U,$J,358.3,16948,1,4,0)
 ;;=4^G72.49
 ;;^UTILITY(U,$J,358.3,16948,2)
 ;;=^5004099
 ;;^UTILITY(U,$J,358.3,16949,0)
 ;;=G72.2^^88^856^99
 ;;^UTILITY(U,$J,358.3,16949,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16949,1,3,0)
 ;;=3^Myopathy,Other Toxic Agents
 ;;^UTILITY(U,$J,358.3,16949,1,4,0)
 ;;=4^G72.2
 ;;^UTILITY(U,$J,358.3,16949,2)
 ;;=^5004097
 ;;^UTILITY(U,$J,358.3,16950,0)
 ;;=G72.3^^88^856^100
 ;;^UTILITY(U,$J,358.3,16950,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16950,1,3,0)
 ;;=3^Myopathy,Periodic Paralysis
 ;;^UTILITY(U,$J,358.3,16950,1,4,0)
 ;;=4^G72.3
 ;;^UTILITY(U,$J,358.3,16950,2)
 ;;=^335326
 ;;^UTILITY(U,$J,358.3,16951,0)
 ;;=G72.9^^88^856^101
 ;;^UTILITY(U,$J,358.3,16951,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16951,1,3,0)
 ;;=3^Myopathy,Unspec
 ;;^UTILITY(U,$J,358.3,16951,1,4,0)
 ;;=4^G72.9
 ;;^UTILITY(U,$J,358.3,16951,2)
 ;;=^5004101
 ;;^UTILITY(U,$J,358.3,16952,0)
 ;;=M60.9^^88^856^102
 ;;^UTILITY(U,$J,358.3,16952,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16952,1,3,0)
 ;;=3^Myositis,Unspec
 ;;^UTILITY(U,$J,358.3,16952,1,4,0)
 ;;=4^M60.9
 ;;^UTILITY(U,$J,358.3,16952,2)
 ;;=^5012409
 ;;^UTILITY(U,$J,358.3,16953,0)
 ;;=M79.2^^88^856^103
 ;;^UTILITY(U,$J,358.3,16953,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16953,1,3,0)
 ;;=3^Neuralgia & Neuritis,Unspec
 ;;^UTILITY(U,$J,358.3,16953,1,4,0)
 ;;=4^M79.2
 ;;^UTILITY(U,$J,358.3,16953,2)
 ;;=^5013322
 ;;^UTILITY(U,$J,358.3,16954,0)
 ;;=M54.81^^88^856^104
 ;;^UTILITY(U,$J,358.3,16954,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16954,1,3,0)
 ;;=3^Neuralgia,Occipital
 ;;^UTILITY(U,$J,358.3,16954,1,4,0)
 ;;=4^M54.81
 ;;^UTILITY(U,$J,358.3,16954,2)
 ;;=^5012312
 ;;^UTILITY(U,$J,358.3,16955,0)
 ;;=M89.70^^88^856^106
 ;;^UTILITY(U,$J,358.3,16955,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16955,1,3,0)
 ;;=3^Osseous Defect,Major,Unspec Site
 ;;^UTILITY(U,$J,358.3,16955,1,4,0)
 ;;=4^M89.70
 ;;^UTILITY(U,$J,358.3,16955,2)
 ;;=^5015085
 ;;^UTILITY(U,$J,358.3,16956,0)
 ;;=M79.81^^88^856^105
 ;;^UTILITY(U,$J,358.3,16956,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16956,1,3,0)
 ;;=3^Nontraumatic Hematoma,Soft Tissue
